AR126011A1 - Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos - Google Patents
Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidosInfo
- Publication number
- AR126011A1 AR126011A1 ARP220101437A ARP220101437A AR126011A1 AR 126011 A1 AR126011 A1 AR 126011A1 AR P220101437 A ARP220101437 A AR P220101437A AR P220101437 A ARP220101437 A AR P220101437A AR 126011 A1 AR126011 A1 AR 126011A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyrrolo
- substituted phenyl
- pyridine derivatives
- menin
- mpn
- Prior art date
Links
- BEXAOGSITTZUEY-UHFFFAOYSA-N 1-phenylpyrrolo[2,3-c]pyridine Chemical class C1=CC2=CC=NC=C2N1C1=CC=CC=C1 BEXAOGSITTZUEY-UHFFFAOYSA-N 0.000 title 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 101710169972 Menin Proteins 0.000 abstract 1
- 102100030550 Menin Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero, a una composición farmacéutica que comprende tales compuestos y a su uso como inhibidores de la interacción entre las proteínas menina y MLL útiles para tratar enfermedades tales como el cáncer, que incluye, sin carácter limitante, leucemia, síndrome mielodisplásico (SMD) y neoplasias mieloproliferativas (NMP); y diabetes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021097679 | 2021-06-01 | ||
CN2022085680 | 2022-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR126011A1 true AR126011A1 (es) | 2023-08-30 |
Family
ID=82016507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220101437A AR126011A1 (es) | 2021-06-01 | 2022-05-31 | Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230250096A1 (es) |
EP (1) | EP4347588A1 (es) |
KR (1) | KR20240016324A (es) |
CN (1) | CN117396476A (es) |
AR (1) | AR126011A1 (es) |
AU (1) | AU2022286467A1 (es) |
CA (1) | CA3218479A1 (es) |
CO (1) | CO2023016217A2 (es) |
EC (1) | ECSP23095641A (es) |
IL (1) | IL308862A (es) |
TW (1) | TW202313606A (es) |
UY (1) | UY39795A (es) |
WO (1) | WO2022253167A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023193790A1 (en) | 2022-04-08 | 2023-10-12 | Janssen Pharmaceutica Nv | Crystalline forms of an inhibitor of the menin/mll interaction |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010289321A1 (en) | 2009-09-04 | 2012-04-05 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
WO2011056440A1 (en) | 2009-10-27 | 2011-05-12 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as ccr1 receptor antagonists |
GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
EP2755974A1 (en) | 2011-09-14 | 2014-07-23 | Proximagen Limited | New enzyme inhibitor compounds |
CN105188705A (zh) | 2013-03-13 | 2015-12-23 | 密歇根大学董事会 | 包含噻吩并嘧啶和噻吩并吡啶化合物的组合物及其使用方法 |
WO2014199171A1 (en) | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
WO2016197027A1 (en) | 2015-06-04 | 2016-12-08 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
AR104020A1 (es) | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
EP3394064A1 (en) | 2015-12-22 | 2018-10-31 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
AU2017212572A1 (en) | 2016-01-26 | 2018-08-23 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
HRP20230537T1 (hr) | 2016-03-16 | 2023-08-04 | Kura Oncology, Inc. | Supstituirani derivati tieno[2,3-d]pirimidina kao inhibitori za menin-mll i postupci za uporabu |
JP7000333B2 (ja) | 2016-03-16 | 2022-02-10 | クラ オンコロジー,インク. | メニン-mllの架橋された二環式阻害剤及びその使用方法 |
CN109415337B (zh) | 2016-05-02 | 2022-01-18 | 密执安大学评议会 | 作为多发性内分泌腺瘤蛋白抑制剂的哌啶 |
WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
ES2831084T3 (es) | 2016-06-10 | 2021-06-07 | Vitae Pharmaceuticals Inc | Inhibidores de la interacción menina-MLL |
WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
AU2017326485B2 (en) | 2016-09-14 | 2021-04-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-MLL interaction |
CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
MX2019003091A (es) | 2016-09-16 | 2019-07-08 | Vitae Pharmaceuticals Inc | Inhibidores de la interaccion de menina-mll. |
WO2018106820A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
WO2018106818A1 (en) | 2016-12-07 | 2018-06-14 | Kura Oncology, Inc. | Methods of promoting beta cell proliferation |
WO2018109088A1 (en) | 2016-12-15 | 2018-06-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-mll interaction |
CN108456208B (zh) | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
EP3601249A4 (en) | 2017-03-24 | 2020-12-16 | Kura Oncology, Inc. | METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
TW201920170A (zh) | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
WO2020069027A1 (en) | 2018-09-26 | 2020-04-02 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
US20220380365A1 (en) | 2019-09-27 | 2022-12-01 | Sumitomo Dainippon Pharma Co., Ltd. | Crosslinked optically active secondary amine derivative |
EP4077312A4 (en) | 2019-12-19 | 2024-01-17 | Janssen Pharmaceutica Nv | SUBSTITUTED STRAIGHT CHAIN SPIRO DERIVATIVES |
-
2022
- 2022-05-30 WO PCT/CN2022/095901 patent/WO2022253167A1/en active Application Filing
- 2022-05-30 CA CA3218479A patent/CA3218479A1/en active Pending
- 2022-05-30 IL IL308862A patent/IL308862A/en unknown
- 2022-05-30 EP EP22729029.3A patent/EP4347588A1/en active Pending
- 2022-05-30 AU AU2022286467A patent/AU2022286467A1/en active Pending
- 2022-05-30 KR KR1020237044791A patent/KR20240016324A/ko unknown
- 2022-05-30 US US18/015,661 patent/US20230250096A1/en active Pending
- 2022-05-30 CN CN202280039035.9A patent/CN117396476A/zh active Pending
- 2022-05-31 TW TW111120214A patent/TW202313606A/zh unknown
- 2022-05-31 AR ARP220101437A patent/AR126011A1/es unknown
- 2022-06-01 UY UY0001039795A patent/UY39795A/es unknown
-
2023
- 2023-11-29 CO CONC2023/0016217A patent/CO2023016217A2/es unknown
- 2023-12-28 EC ECSENADI202395641A patent/ECSP23095641A/es unknown
Also Published As
Publication number | Publication date |
---|---|
UY39795A (es) | 2022-11-30 |
WO2022253167A1 (en) | 2022-12-08 |
TW202313606A (zh) | 2023-04-01 |
US20230250096A1 (en) | 2023-08-10 |
CO2023016217A2 (es) | 2023-12-11 |
WO2022253167A8 (en) | 2023-03-09 |
KR20240016324A (ko) | 2024-02-06 |
CN117396476A (zh) | 2024-01-12 |
IL308862A (en) | 2024-01-01 |
ECSP23095641A (es) | 2024-01-31 |
CA3218479A1 (en) | 2022-12-08 |
AU2022286467A1 (en) | 2024-01-25 |
EP4347588A1 (en) | 2024-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001583A1 (es) | Derivados espiráncos sustituidos de cadena lineal | |
ECSP23095641A (es) | Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos | |
PA8523001A1 (es) | Derivados de la 3-indolil-4-fenil-1h-pirrol-2,5-diona como inhibidores de glicogeno sintasa quinasa-3b | |
BR112019004764A2 (pt) | inibidores bicíclicos fundidos da interação menina-mll | |
GT200600398A (es) | Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso | |
SV2008002967A (es) | Derivados de pirimidinil-aril-urea que son inhibidores de fgf | |
ECSP066928A (es) | Derivados de carbolina útiles en la inhibición de la angiogénesis | |
MX2019002962A (es) | Inhibidores espirobiciclicos de la interaccion de menina-mll. | |
UY35293A (es) | Isotiazoles sustituidos con amino | |
UY29325A1 (es) | Nuevos derivados de 2 - amino-piridina | |
CR10056A (es) | [(1h-indol-5-il)-heteroariloxi]-(1-aza-biciclo[3.3.1]nonanos como ligandos colinérgicos del n-achr para el tratamiento de trastornos piscóticos y neurodegenerativos | |
AR051472A1 (es) | Uso de inhibidores de las quinasas jun n- terminales para eltratamiento de la retinopatia glaucomatosa y enfermedades oculares | |
UY29343A1 (es) | Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso. | |
AR070783A1 (es) | Forma de cristal de derivados de fenilamina-pirimidina | |
HN2003000162A (es) | Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen. | |
CL2023001220A1 (es) | Inhibidores de interleucina-17 | |
BR112023023463A2 (pt) | Inibidores da interação menin-mll | |
ECSP088472A (es) | Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento | |
CO2023018577A2 (es) | Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncer | |
BR112023021040A2 (pt) | Derivados espiro substituídos | |
BR112023025436A2 (pt) | Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas | |
BR112019012106A2 (pt) | inibidores de azepano de interação menin-mill | |
ECSP23019518A (es) | Derivados de tetrahidroisoquinolina para el tratamiento de eritrocitos y enfermedades inflamatorias | |
AR120802A1 (es) | Derivados espiráncos sustituidos de cadena lineal | |
UY39865A (es) | Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer |